193 related articles for article (PubMed ID: 27092876)
1. Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma.
Xie H; Zhu Y; An H; Wang H; Zhu Y; Fu H; Wang Z; Fu Q; Xu J; Ye D
Oncotarget; 2016 May; 7(22):32723-30. PubMed ID: 27092876
[TBL] [Abstract][Full Text] [Related]
2. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
3. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
[TBL] [Abstract][Full Text] [Related]
4. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
6. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
7. Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Zhang H; Liu Y; Xie H; Fu Q; Liu Z; Zhu Y; Xu L; Zhang W; Yang Y; Xu J
Tumour Biol; 2017 Feb; 39(2):1010428317691417. PubMed ID: 28231735
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
[TBL] [Abstract][Full Text] [Related]
9. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
10. High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.
Wang J; Xu Y; Zhu L; Zou Y; Kong W; Dong B; Huang J; Chen Y; Xue W; Huang Y; Zhang J
PLoS One; 2016; 11(11):e0166231. PubMed ID: 27861513
[TBL] [Abstract][Full Text] [Related]
11. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
[TBL] [Abstract][Full Text] [Related]
12. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma.
Lee C; Park JW; Suh JH; Moon KC
Pathol Res Pract; 2015 Nov; 211(11):824-8. PubMed ID: 26296917
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of UTX expression in patients with clear cell renal cell carcinoma.
Wang J; Liu L; Xi W; Long Q; Wang Y; Bai Q; Xia Y; Xu J; Guo J
Urol Oncol; 2016 Aug; 34(8):338.e19-27. PubMed ID: 27106782
[TBL] [Abstract][Full Text] [Related]
14. p21-activated kinase 1 predicts recurrence and survival in patients with non-metastatic clear cell renal cell carcinoma.
Zhu Y; Xu L; An H; Liu W; Wang Z; Xu J
Int J Urol; 2015 May; 22(5):447-53. PubMed ID: 25711487
[TBL] [Abstract][Full Text] [Related]
15. Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma.
Xi W; Liu L; Wang J; Xia Y; Bai Q; Xiong Y; Qu Y; Long Q; Xu J; Guo J
Oncotarget; 2016 Dec; 7(49):80925-80934. PubMed ID: 27821813
[TBL] [Abstract][Full Text] [Related]
16. Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma.
Wu Q; Yang L; Liu H; Zhang W; Le X; Xu J
Ann Surg Oncol; 2015 Jul; 22(7):2446-53. PubMed ID: 25391266
[TBL] [Abstract][Full Text] [Related]
17. IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma.
Bai Q; Liu L; Xia Y; Wang J; Xi W; Qu Y; Xiong Y; Long Q; Xu J; Guo J
Oncotarget; 2017 Jul; 8(27):44186-44194. PubMed ID: 28562332
[TBL] [Abstract][Full Text] [Related]
18. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
[TBL] [Abstract][Full Text] [Related]
19. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
20. High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.
Yang L; Liu Y; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Ann Surg Oncol; 2016 Mar; 23(3):1044-52. PubMed ID: 26467457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
